Author: Wu, S.; Zou, G.; Lin, K.; Zhang, D.
Title: Effects of covid-19 on the cardiovascular system and implications for management Cord-id: n8ljf5p3 Document date: 2021_1_1
ID: n8ljf5p3
Snippet: Coronavirus disease 2019 (COVID-2019) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may affect the cardiovascular system in multiple ways causing acute cardiac injury, cardiac ischemia, arrhythmias and sudden cardiac deaths. Fulminant SARS-CoV-2 viral myocarditis have been reported, though it is likely relatively rare. In both children and adults, COVID-19 may also cause a Kawasaki-like multisystem inflammatory syndrome with heart involvement being a prominent featur
Document: Coronavirus disease 2019 (COVID-2019) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may affect the cardiovascular system in multiple ways causing acute cardiac injury, cardiac ischemia, arrhythmias and sudden cardiac deaths. Fulminant SARS-CoV-2 viral myocarditis have been reported, though it is likely relatively rare. In both children and adults, COVID-19 may also cause a Kawasaki-like multisystem inflammatory syndrome with heart involvement being a prominent feature. Possible mechanisms of cardiovascular injury in COVID-19 include hypoxia from lung disease, direct viral infection of cells in the cardiovascular system, down-regulation of angiotensin converting enzyme 2 (ACE2), dysregulated immune response, endothelial dysfunction, and thrombosis. Medications used to treat COVID-19 may also have cardiac side effects including QT-prolongation and arrhythmias. Troponin elevation or acute cardiac injury may be used to risk-stratify patients with severe COVID-19. The dysregulated immune response in COVID-19 can be targeted with glucocorticoids and possibly immunomodulators. Anticoagulation may be indicated in select COVID-19 patients to prevent or treat thrombotic complications. The relationship between angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) and COVID-19 is not completely understood and major societies have recommended that patients who were otherwise benefiting from ACEIs or ARBs continue to take it. © Journal of Xiangya Medicine. All rights reserved.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- acute respiratory syndrome and lung disease hypoxia: 1
Co phrase search for related documents, hyperlinks ordered by date